01 02 03 Financial Statements 04 Consolidated Statement of Comprehensive Income For the year ended 31 December (thousands of Georgian Lari) Year ended Year ended 31 December 31 December Notes 2018 2017 Healthcare services revenue 26 291,069 253,612 Revenue from pharma 26 501,090 438,358 Net insurance premiums earned 27 54,147 53,741 Revenue 846,306 745,711 Cost of healthcare services 28 (155,926) (139,726) Cost of sales of pharmaceuticals 28 (386,152) (339,460) Cost of insurance services and agents’ commissions 29 (35,627) (38,526) Costs of services (577,705) (517,712) Gross profit 268,601 227,999 Other operating income 30 18,120 21,483 Salaries and other employee benefits 31 (84,509) (75,430) General and administrative expenses 32 (54,436) (48,618) Impairment of healthcare services, insurance premiums and other receivables 33 (4,448) (4,175) Other operating expenses 34 (11,054) (13,111) (154,447) (141,334) EBITDA 132,274 108,148 Depreciation and amortisation 11, 12 (33,883) (25,704) Interest income 35 1,139 2,111 Interest expense 35 (39,315) (27,543) Net losses from foreign currencies and cost of currency derivatives (4,173) (5,906) Net non-recurring expense 36 (2,187) (4,780) Profit before income tax expense 53,855 46,326 Income tax expense 13 (616) (77) Non-recurring deferred tax expense 13 – (309) Profit for the year 53,239 45,940 Other comprehensive loss not to be reclassified to profit or loss in subsequent periods: revaluation of properties 11 – (4,866) Total comprehensive income for the year 53,239 41,074 Profit for the year attributable to: – shareholders of the Company 34,434 29,110 – non-controlling interests 18,805 16,830 Total comprehensive income for the year attributable to: – shareholders of the Company 34,434 24,650 – non-controlling interests 18,805 16,424 Earnings per share (profit for the year): – basic earnings per share 25 0.27 0.23 – diluted earnings per share 25 0.26 0.22 Earnings per share (total comprehensive income): – basic earnings per share 25 0.27 0.19 – diluted earnings per share 25 0.26 0.19 The accompanying notes on pages 128 to 175 form an integral part of these consolidated Financial Statements. 125